Well, not completely but pretty much. All of the catalysts say BUY this one. 3 separate markets of untreated need with no currently available treatment, each with a HUGE rate of incidence translates into a massive market cap once these get approval. The drug itself is already on the market for use in treating Dupuytren's contracture- a condition for which Auxillium offers the only non surgical treatment and which is currently bringing in significant revenue. That revenue could quadruple or more over the next 3 years.